Long-term study of people with recent HIV-1 infection in Zurich
Observes people newly infected with HIV-1 to learn how early infection progresses.
Key facts
- Who runs it
- University of Zurich
- Where
- Zurich, SwitzerlandSee the site
- Trial code
- Registry title
- Characterization of Acute and Recent HIV-1 Infections in Zurich.
- Status
- Recruiting
- People taking part
- 800 people, planned
- Started
- Jan 2002
- Expected to end
- Dec 2028
- Type of study
- Observational
- Record updated
- 17 December 2024
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a recent HIV-1 infection, either acute (within 90 days) or recent (within 180 days). It follows them over a long time.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Acute HIV-1 infection (infection documented within 90 days) or recent HIV-1 infection (within 180 days), with or without symptoms.
- Biomarker or test result
- Acute: negative or still-developing immunoblot with positive p24 antigen and/or detectable HIV-1 RNA in the blood, or a documented HIV seroconversion within 90 days. Recent: documented seroconversion between 90 and 180 days, or a risk event within 180 days.
Main reasons for not taking part
- HIV infection diagnosed more than 180 days after the presumed date of infection
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- acute HIV-1 infection, defined as:
- negative or evolving immunoblot in the presence of positive p24 Ag and/or detectable plasma HIV-1 RNA and/or
- documented HIV seroconversion within 90 dayswith or with-out symptoms and/or clinical signs of PHI (e.g. acute retro-viral syndrome)
- recent HIV-1 infection, defined as:
- documented seroconversion of more than 90 days but within 180 days and/or
- evolving immunoblot after unambiguous transmission risk (e.g. iv drug use, sexual contact) within 180 days and/or
- documented HIV infection and unambiguous transmission risk (iv drug use, sexual contact) within 180 days and/or
- documented HIV infection and possible transmission risk (iv drug use, sexual contact) within the last 180 days after infection AND < 0.5% fraction of ambiguous nucleotides
Who cannot take part
- Documented HIV infection, however, established diagnosis more than 180 days after presumed date of infection
Where in Switzerland
- University of ZurichZurich, SwitzerlandContact: Huldrych. GünthardTaking people
About the trial
What the trial wants to find out
Aim of the study: To study and to describe factors which could influence the course of primary HIV infection (PHI) and factors that in turn could be influenced through PHI.
Read full original descriptionShow less
In summary, this study will provide comprehensive knowledge on early HIV-infection with regard to epidemiology, impact of early-cART on the course of disease and forms the base for a variety of translational research projects addressing early key pathogenesis events between virus and host, relevant for the course of disease, for transmission, for development of vaccines and new treatment strategies.
The group in the trial
- Primo - Cohort
The patients with primary HIV-1 infection will receive combination antiretroviral therapy with standard drugs approved by Swiss Medic.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Characterization of Acute and Recent HIV-1 Infections in Zurich. a Long-term Observational Study: the Zurich Primary HIV Infection Study.
- Plain-language title
- Long-term study of people with recent HIV-1 infection in ZurichGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 17 December 2024